Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Rizzo JF 3rd et al
8 CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity, currently in Phase I, with the potential to be a best-in-class oral treatment for type 2 diabetes and chronic weight management
This is a structured program that treats both physical sleep system disruptions that lead to sleeplessness, and helps you identify and manage thoughts and behaviors that are causing or worsening your sleep problems
CLA (Conjugated Linoleic Acid) Blocks fat and carb absorption, lowers cholesterol and triglycerides
US$ 22.25
US$ 29.77
US$ 21.21
US$ 23.40
US$ 21.88
US$ 29.38
US$ 24.92
US$ 27.38
